COX-2 selective inhibitors (coxibs): Gastrointestinal safety

Research output: Contribution to journalReview article

11 Citations (Scopus)


COX-2 selective inhibitors (coxibs) have been developed with the primary aim to reduce/avoid gastrointestinal (GI) toxicity observed during conventional (non-selective) non-steroidal anti-inflammatory (NSAID) therapy. Coxibs have clearly and convincingly been shown to be superior to conventional NSAIDs with significantly less GI side effects. When hard endpoints such as perforation, obstruction, and serious bleeding considered, coxibs reduce the risk by approximately 50%. Although selective COX-2 inhibition seems not to be enough for complete elimination of GI toxicity, coxibs posses no more GI toxicity than placebo in prospective clinical studies and further increase in COX-2 selectivity does not reduce GI toxicity. For the initial aim developed, thus coxibs fulfilled their promise and will soon replace conventional NSAIDs.

Original languageEnglish
Pages (from-to)23-30
Number of pages8
JournalInternational Journal of Immunopathology and Pharmacology
Issue number2 SUPPL.
Publication statusPublished - May 1 2003


  • COX-2 selective inhibitors
  • Coxib
  • Gastrointestinal toxicity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Fingerprint Dive into the research topics of 'COX-2 selective inhibitors (coxibs): Gastrointestinal safety'. Together they form a unique fingerprint.

  • Cite this